Global Anti-Inflammatory Drugs Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	195 Pages	DataM Intelligence 4Market Research LLP	June, 2023	DTAM18020138

Best Price Guarantee
Price	from $4,350
Length	195 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	June, 2023
SKU	DTAM18020138

Global Anti-Inflammatory Drugs Market - 2023-2030

The Global Anti-Inflammatory Drugs Market reached US$ 87.7 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 170.1 billion by 2030. The Global Anti-Inflammatory Drugs Market is expected to exhibit a CAGR of 8.8% during the forecast period 2023-2030.

Anti-inflammatory drugs act by inhibiting particular molecules in the body that cause inflammation. They treat various ailments such as migraines, headaches, rheumatoid arthritis, sprains, and menstruation discomfort.

Several factors drive the Global Anti-Inflammatory Market due to the increasing prevalence of autoimmune and respiratory disorders, the discovery of novel treatments in the pipeline, and the increased use of anti-inflammatory medications. Furthermore, the demand for anti-inflammatory drug has been quickly increasing as a result of the development of tailored and highly effective anti-inflammatory biologics, which have fewer adverse effects than traditional treatments.

Market Dynamics

The Advancements in Technology is Expected to Drive the Global Anti-Inflammatory Market

Technology advancements, such as targeted drug delivery systems, novel drug formulations, and the development of new drug administration methods, are driving considerable growth in the worldwide anti-inflammatory medications market.

For instance, UConn Pharmacy researchers have created a ground-breaking technology for administering nonsteroidal anti-inflammatory medicines (NSAIDs) known as long-acting injectable NSAIDs that allow sustained release over time.

This advancement offers the potential to lessen or eliminate the negative consequences associated with long-term NSAID use. These advances provide good possibilities for the global anti-inflammatory drugs market, potentially improving patient outcomes and revolutionizing the treatment of inflammatory disorders.

The Global Anti-Inflammatory Drugs Market May Face Constraints Due to the Stringent Regulatory Approvals

The extensive regulatory clearance procedure frequently causes delays in the introduction of new anti-inflammatory medications to the market. To show its safety, effectiveness, and quality standards, a pharmaceutical firm developing a novel anti-inflammatory medicine must undergo comprehensive preclinical investigations and numerous phases of clinical trials.

These studies entail recruiting and monitoring a large number of patients over a long period of time. Owing to this reason, the global anti-inflammatory drugs market will face a major restraint over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic is expected to have a favourable effect on the market for anti-inflammatory drugs since the illness causes inflammation in those afflicted.

COVID-19 is caused by the beta coronavirus SARS-CoV-2, which can cause severe pneumonia with increased inflammation. According to studies, Cytokine storms play a substantial role in these individuals' deaths. Severe inflammation and cytokine storms can result in many organ dysfunction syndromes, acute lung injury, acute respiratory distress syndrome, and other effects. As a result, efforts to produce anti-inflammatory drugs to treat COVID-19-induced inflammation have risen.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war has substantially influenced the global anti-inflammatory drugs industry. The conflict has altered trade dynamics, affecting the supply chain, the pricing of raw materials, and the availability of pharmaceuticals. Negative consequences are expected all throughout the world, notably in Eastern Europe, the European Union, Eastern and Central Asia, and the United States.

The conflict has caused the Ukrainian economy to collapse, resulting in significant decreases in medicine manufacture and distribution and significant price rises. The crisis has influenced the worldwide market for nonsteroidal anti-inflammatory drugs, putting pressure on pricing choices and altering import/export and trade activities.

Segment Analysis

The Global Anti-Inflammatory Drugs Market is segmented based on indication, drug class, distribution channel, and region.

The Anti-Inflammatory Biologics Segment is Expected to Dominate the Global Anti-Inflammatory Drugs Market

In drug class, the anti-inflammatory biologics segment is projected to dominate the anti-inflammatory drugs market. It will account the highest market share of 34.3% due to their targeted delivery approach, enhanced efficacy, personalized medicine potential, and the increasing number of indications that are addressed by these biologics, making them a forefront runner.

Anti-inflammatory biologics are rapidly gaining a commanding position in the worldwide anti-inflammatory medicines industry. Biologics are medications generated from live organisms that target specific inflammatory pathways or substances in the body.

Many companies in the U.S. invest in biologics and its biosimilar to make it cost-effective for the people. For instance, in January 2023, AMJEVITA (adalimumab-atto), a biosimilar of Humira (adalimumab), was introduced by Amgen and is currently accessible in the United States.

In 2016, the US Food and Drug Administration (FDA) authorized AMJEVITA as the first biosimilar of Humira. It is a medication used by over a million individuals suffering from severe inflammatory illnesses. Therefore, owing to the above factor, the Global Anti-Inflammatory market is expected to fuel over the forecast period.

Geographical Analysis

North America Region Holds the Largest Market Share of the Global Anti-Inflammatory Drugs Market

North America is expected to hold a dominant position in the global anti-inflammatory drugs market, clinching a 38.7% share of the total market due to the growing elderly population, better healthcare spending, technological advancements, presence of major market players leading to drug development, and the advanced healthcare infrastructure.

Age-related illnesses, including osteoporosis, cardiovascular disease, and arthritis, become increasingly common. These ailments frequently entail persistent inflammation, which raises the demand for anti-inflammatory medications. For instance, according to World Health Organization 2022 report, by 2030, one out of every six persons in this world will be 60 or older.

The number of people aged 60 and more is expected to grow from 1 billion in 2020 to 1.4 billion by 2030. Therefore, the growing aging population is expected to dominate North America's global anti-inflammatory drugs market over the forecast period.

Competitive Landscape

The major global players in the market include Amgen Inc, AstraZeneca, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb, F-Hoffmann-La-Roche, Eli Lilly, Sanofi, Abbot Laboratories, and Boehringer Ingelheim GmbH.

Why Purchase the Report?
• To visualize Global Anti-Inflammatory Drugs Market segmentation based on indication, drug class, distribution channel, and region- and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous global anti-inflammatory drugs market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Anti-Inflammatory Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Market Snippet By Indication; 3.2. Market Snippet by Drug Class; 3.3. Market Snippet by Distribution Channel; 3.4. Market Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Advancements in technology; 4.1.2. Restraints; 4.1.2.1. Stringent regulatory approvals; 4.1.3. Opportunity; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter's 5 Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Scenario Before COVID-19; 6.1.2. Scenario During COVID-19; 6.1.3. Post COVID-19 & Future Scenario; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During the Pandemic; 6.5. Manufacturer’s Strategic Initiatives; 6.6. Conclusion
7. By Indication: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 7.1.2. Market Attractiveness Index, By Indication; 7.2. Arthritis; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. Chronic obstructive pulmonary disease (COPD); 7.4. Multiple Sclerosis; 7.5. Inflammatory bowel disease (IBD); 7.6. Asthma; 7.7. Tendonitis; 7.8. Other
8. By Drug Class: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 8.1.2. Market Attractiveness Index, By Drug Class; 8.2. Anti-Inflammatory Biologics; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. Nonsteroidal anti-inflammatory drugs (NSAIDS); 8.4. Corticosteroids; 8.5. Immune-selective anti-inflammatory derivative (IMSAID); 8.6. Others
9. By Distribution Channel: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 9.1.2. Market Attractiveness Index, By Distribution Channel; 9.2. Hospital Pharmacies; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.3. Retail Pharmacies; 9.4. Online Pharmacies
10. By Region: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 10.1.2. Market Attractiveness Index, By Region; 10.2. North America; 10.2.1. Introduction; 10.2.2. Key Region-Specific Dynamics; 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.2.6.1. The U.S.; 10.2.6.2. Canada; 10.2.6.3. Mexico; 10.3. Europe; 10.3.1. Introduction; 10.3.2. Key Region-Specific Dynamics; 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.3.6.1. Germany; 10.3.6.2. The UK; 10.3.6.3. France; 10.3.6.4. Italy; 10.3.6.5. Spain; 10.3.6.6. Rest of Europe; 10.4. South America; 10.4.1. Introduction; 10.4.2. Key Region-Specific Dynamics; 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution; 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.4.6.1. Brazil; 10.4.6.2. Argentina; 10.4.6.3. Rest of South America; 10.5. Asia-Pacific; 10.5.1. Introduction; 10.5.2. Key Region-Specific Dynamics; 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.5.6.1. China; 10.5.6.2. India; 10.5.6.3. Japan; 10.5.6.4. Australia; 10.5.6.5. Rest of Asia-Pacific; 10.6. Middle East and Africa; 10.6.1. Introduction; 10.6.2. Key Region-Specific Dynamics; 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape: 11.1. Competitive Scenario; 11.2. Market Positioning/Share Analysis; 11.3. Mergers and Acquisitions Analysis
12. Company Profiles: 12.1. Amgen Inc*; 12.1.1. Company Overview; 12.1.2. Product Portfolio and Description; 12.1.3. Financial Overview; 12.1.4. Key Developments; 12.2. AstraZeneca; 12.3. Merck & Co.; 12.4. GlaxoSmithKline; 12.5. Bristol-Myers Squibb; 12.6. F-Hoffmann-La-Roche; 12.7. Eli Lilly; 12.8. Sanofi; 12.9. Abbott Laboratories; 12.10. Boehringer Ingelheim GmbH; LIST NOT EXHAUSTIVE
13. Appendix: 13.1. About Us and Services; 13.2. Contact Us